TY - JOUR
T1 - Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer
AU - Veccia, Antonello
AU - Caffo, Orazio
AU - De Giorgi, Ugo
AU - Di Lorenzo, Giuseppe
AU - Ortega, Cinzia
AU - Scognamiglio, Florinda
AU - Aieta, Michele
AU - Facchini, Gaetano
AU - Mansueto, Giovanni
AU - Mattioli, Rodolfo
AU - Procopio, Giuseppe
AU - Zagonel, Vittorina
AU - D'Angelo, Alessandro
AU - Spizzo, Gilbert
AU - Bortolus, Roberto
AU - Donini, Maddalena
AU - Lo Re, Giovanni
AU - Massari, Francesco
AU - Vicario, G.
AU - Zucali, Paolo Andrea
AU - Alesini, Daniele
AU - Bonetti, A.
AU - Mucciarini, C.
AU - Nicodemo, M.
AU - Berruti, Alfredo
AU - Fratino, Lucia
AU - Lodde, Michele
AU - Messina, Caterina
AU - Perin, A.
AU - Santini, Daniele
AU - Sava, T.
AU - Tucci, Marcello
AU - Basso, Umberto
AU - Maines, Francesca
AU - Burgio, Salvatore Luca
AU - Galligioni, E.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Aim: To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer. Patients & methods: The multicenter retrospective study was based on a review of the pre-and post-DOC clinical history, DOC treatment and outcomes. Results: We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3-4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival. Conclusion: The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.
AB - Aim: To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer. Patients & methods: The multicenter retrospective study was based on a review of the pre-and post-DOC clinical history, DOC treatment and outcomes. Results: We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3-4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival. Conclusion: The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.
KW - castration-resistant prostate cancer
KW - docetaxel
KW - elderly
KW - geriatric assessment
UR - http://www.scopus.com/inward/record.url?scp=84957695804&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957695804&partnerID=8YFLogxK
U2 - 10.2217/fon.15.302
DO - 10.2217/fon.15.302
M3 - Article
VL - 12
SP - 493
EP - 502
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 4
ER -